Skip to Main Content

INTRODUCTION

retapamulin (re-ta-pam-yoo-lin)

Altabax

Classification

Therapeutic: anti-infectives

Pharmacologic: pleuromutilins

Indications

Topical treatment of impetigo caused by methicillinsusceptible Staphylococcus aureus or Streptococcus pyogenes.

Action

Interferes with bacterial protein synthesis at the level of the 50S ribosome. Therapeutic Effects: Bacteriostatic action against susceptible organisms.

Adverse Reactions/Side Effects

Derm: application site irritation.

PHYSICAL THERAPY IMPLICATIONS

Examination and Evaluation

  • Assess the area being treated to help determine if drug therapy is successful in resolving skin conditions.

  • Monitor any new or increased skin reactions at the site of application, including rash, itching, burning, or other suspicious skin lesions. Report severe or unusual skin reactions to the physician.

Interventions

  • Always wash hands thoroughly and disinfect equipment (whirlpools, electrotherapeutic devices, treatment tables, and so forth) to help prevent the spread of infection. Use universal precautions or isolation procedures as indicated for specific patients.

Patient/Client-Related Instruction

  • Check that the patient and family or caregivers understand topical application procedures, and adhere to the recommended dosing schedule.

  • Instruct patient with skin lesions to avoid itching or scratching the affected area. Patients should avoid contact with other individuals (e.g., other athletes) during the active phase of the infection.

Pharmacokinetics

Absorption: Minimal systemic absorption.

Distribution: Unknown.

Metabolism and Excretion: Small amounts absorbed are extensively metabolized.

Half-life: Unknown.

Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE

ROUTE ONSET PEAK DURATION
topical unknown unknown 12 hr

Contraindications/Precautions

Contraindicated in: No contraindications.

Use Cautiously in: OB: Use only in pregnancy when maternal benefit outweighs fetal risk; safe use during lactation not established; Pedi: Safe use in children <9 mo not established.

Interactions

Drug-Drug: None.

Route/Dosage

Topical (Adults and Children ≥9 mo): Apply thin layer to affected area (up to 100 cm2 in adults or 2% total body area in children) bid for 5 days.

Availability

Ointment: 10 mg/g in 5-, 10-, and 15-g tubes.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.